Paroxetine: A review of clinical experience

被引:17
作者
Dunner, D [1 ]
Kumar, R
机构
[1] Univ Washington, Med Ctr, Dept Psychiat, Seattle, WA 98195 USA
[2] SmithKline Beecham Pharmaceut, Harlow, Essex, England
关键词
D O I
10.1055/s-2007-979307
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The selective serotonin reuptake inhibitor paroxetine has been extensively studied and is now an established therapy for the treatment of depressive disorders. Paroxetine has demonstrated efficacy in major depression in both young and elderly patients, with an improved tolerability profile over conventional antidepressants. Paroxetine is effective across a continuum of anxiety and depressive disorders, including severe depression, depression with anxiety, comorbid depression and obsessive-compulsive disorder. The first agent of its class licensed for use in panic disorder, paroxetine has been shown to be effective in reducing the number of panic attacks and preventing relapse. A worldwide clinical database has established that paroxetine has a benign adverse event profile. Paroxetine therefore offers an effective and well tolerated treatment for a broad spectrum of psychiatric disorders.
引用
收藏
页码:89 / 101
页数:13
相关论文
共 135 条
[1]   DOUBLE-BLIND-STUDY OF THE EFFICACY AND SAFETY OF SERTRALINE VERSUS FLUOXETINE IN MAJOR DEPRESSION [J].
AGUGLIA, E ;
CASACCHIA, M ;
CASSANO, GB ;
FARAVELLI, C ;
FERRARI, G ;
GIORDANO, P ;
PANCHERI, P ;
RAVIZZA, L ;
TRABUCCHI, M ;
BOLINO, F ;
SCARPATO, A ;
BERARDI, D ;
PROVENZANO, G ;
BRUGNOLI, R ;
ROZZINI, R .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 1993, 8 (03) :197-202
[2]  
Andersen B, 1990, J AFFECT DISORDERS, V18, P289
[3]   COMORBIDITY OF ANXIETY, PHOBIA, COMPULSION AND DEPRESSION [J].
ANGST, J .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 1993, 8 :21-25
[4]  
ANGST J, 1992, PERSPECT PSYCHIATR C, V3, P1
[5]  
[Anonymous], EUROPEAN NEUROPSYCHO
[6]  
[Anonymous], AHCPR PUBL
[7]  
[Anonymous], BRIT J CLIN RES
[8]  
[Anonymous], EUR NEUROPSYCHOPHARM
[9]  
[Anonymous], BRIT J CLIN RES
[10]  
[Anonymous], DEPRESSION, DOI DOI 10.1002/depr.3050020208